A 2C-x compound is a 4-substituted 2,5-dimethoxyphenethylamine — a serotonergic psychedelic defined by a shared chemical scaffold rather than by potency, duration, or use context.[1] Membership is structural: every member carries the same two-methoxy phenethylamine backbone, and the only locus of variation is the substituent at the 4-position of the phenyl ring. The "2C" name, coined by Alexander Shulgin, marks the two carbons between the phenyl ring and the terminal amine.[1]
The class spans halogen-substituted members (2C-B, 2C-C, 2C-I), alkyl-substituted members (2C-D, 2C-E, 2C-P, 2C-H), the thioalkyl 2C-T subfamily (2C-T, 2C-T-2, 2C-T-7, 2C-T-21), and structural variants (2C-B-FLY, βk-2C-B). Despite the variation at the 4-position, all members converge on the same primary mechanism — agonism at serotonin 5-HT2A receptors.
At lower exposures the class produces sensory amplification, colour enhancement, mild perceptual distortion, and a stimulant-like arousal component; at higher exposures the experience deepens into frank visual and auditory hallucinations and altered states of waking consciousness.[2] Members are used recreationally and in psychonautic and harm-reduction-aware communities, and a few — chiefly 2C-B — appear with measurable prevalence in European drug surveillance.
Pharmacology
Across the class, the primary psychoactive mechanism is partial agonism at the serotonin 5-HT2A receptor, with additional activity at 5-HT2B and 5-HT2C.[3] The 4-position substituent modulates receptor affinity, potency, and duration without displacing the serotonergic mechanism that defines the class.
| 4-position substituent | Representative members | Pharmacological signature beyond 5-HT2A agonism |
|---|---|---|
| Halogen (Br, Cl, I) | 2C-B, 2C-C, 2C-I | Partial 5-HT2B/2C agonism with weak inhibition of serotonin and norepinephrine reuptake[2] |
| Alkyl (H, methyl, ethyl, n-propyl) | 2C-H, 2C-D, 2C-E, 2C-P | Partial 5-HT2A/2B/2C agonism with weak monoamine reuptake inhibition[4] |
| Thioalkyl (2C-T subfamily) | 2C-T, 2C-T-2, 2C-T-7, 2C-T-21 | High 5-HT2A affinity plus inhibition of monoamine oxidase A and B[5] |
| Conformationally restricted (FLY) | 2C-B-FLY | Methoxy groups locked into receptor-binding geometry, raising 5-HT2 affinity; TAAR1 interaction and a 5-HT2B-driven vasoconstriction signal[6] |
| β-keto | βk-2C-B | Expected to retain 5-HT2A agonism from the preserved 2,5-dimethoxy-4-bromo core; further transporter activity proposed but not characterised in peer-reviewed literature |
The mechanistic detail matters less for the shared experience than the convergent endpoint: all members reach the psychedelic state by activating 5-HT2A, and a head-to-head comparison places 2C-B's alteration of waking consciousness qualitatively in the same psychedelic register as psilocybin.[7] The 2C-T subfamily diverges meaningfully on safety rather than on subjective character. Monoamine oxidase inhibition raises monoamine tone in ways that 5-HT2A agonism alone would not, and that addition shapes the class's worst interaction risks.[5]
Substances
The class is illustrated by members spanning each substituent subgroup:
| Member | Subgroup | Role / distinctive feature |
|---|---|---|
| 2C-B | Halogen | The most prevalent member and the de facto reference compound for the class in clinical and forensic literature[2] |
| 2C-E | Alkyl | The best-characterised alkyl member in controlled human study[4] |
| 2C-I | Halogen | Iodine-substituted analog; documented in case reports of serotonin syndrome and seizures |
| 2C-H | Alkyl (parent) | The unsubstituted parent scaffold; weakly psychoactive and used principally as a chemical reference |
| 2C-T-7 | Thioalkyl (2C-T) | The 2C-T member most often named in serious adverse-event reports, particularly in combination with stimulants or with intranasal use |
| 2C-B-FLY | Conformationally restricted | Dihydrofuran-cyclised analog of 2C-B with higher 5-HT2 affinity and a documented vasoconstriction signal[6] |
| βk-2C-B | β-keto | Beta-keto analog of 2C-B; included primarily by structural relationship in the absence of full receptor-binding characterisation |
These members share the 5-HT2A-driven psychedelic register, but the subgroup to which a member belongs predicts much of its interaction profile and acute-risk picture.
Subjective Effects
Across the class the subjective trajectory tracks a serotonergic-psychedelic axis with a mild stimulant component, deepening as exposure rises.[2]
| Exposure | Characteristic effects |
|---|---|
| Low | Sensory amplification, colour enhancement, mild perceptual distortion, euphoria, and stimulant-like arousal[2] |
| Moderate–high | Frank visual and auditory hallucinations, altered states of waking consciousness, mood and affective shifts, and elevated heart rate and blood pressure[4] |
| High | Intense perceptual restructuring, the potential for panic or psychosis-like states, marked cardiovascular stimulation, and — in the 2C-T subfamily — less predictable monoamine-tone effects from MAO inhibition |
Because the same serotonergic axis drives both the sought perceptual effects and the cardiovascular and psychological risks, the margin between an intense recreational experience and a frankly dangerous one narrows as exposure rises, and narrows further when other serotonergic agents are present.
The 2C-T subgroup is qualitatively similar to the halogen and alkyl members in subjective character but tends to a less predictable course, an experiential pattern consistent with the additional MAO-inhibitory pharmacology.[5]
Safety
Risk profile
The defining acute danger of the 2C-x class is serotonin toxicity when a member is combined with other serotonergic agents — SSRIs, SNRIs, MAOIs, MDMA, tramadol, and other psychedelics. Direct agonism at postsynaptic 5-HT2A (and 5-HT2B/2C) receptors can drive toxic serotonin signalling. A documented 2C-B case produced serotonin syndrome, epileptic seizures, and severe cerebral oedema, with lasting neurological impairment despite hospital care.[8]
For the 2C-T subfamily, the interaction risk escalates. Monoamine oxidase A and B inhibition is documented across thirteen of seventeen 2C-series compounds screened in vitro, with the 2C-T members among the more potent inhibitors.[5]
Combining a 2C-T compound with monoamine-releasing agents, monoamine reuptake inhibitors, or another MAOI raises the risk of serotonin syndrome and hypertensive crisis beyond what 5-HT2A agonism alone would predict.
Cardiovascular stimulation — elevated heart rate and blood pressure — is documented across the halogen and alkyl members and is expected across the class.[2][4] 2C-B-FLY carries an additional vasoconstriction signal through potent 5-HT2B activation, of particular concern for anyone with cardiovascular vulnerability.[6]
A practical detection note: 2C-x compounds are not reliably picked up by standard hospital drug-of-abuse screening, which has complicated emergency diagnosis in confirmed-toxicity cases.[8] Acute psychological distress — panic, anxiety, and psychosis-like states — can occur at higher exposures, consistent with the serotonergic psychedelic mechanism.
Tolerance & dependence
Tolerance develops rapidly across the class via 5-HT2A receptor downregulation, the same mechanism documented for other serotonergic psychedelics.[9] Cross-tolerance is expected within the class — recent use of one member diminishes the effects of others — and extends to other serotonergic psychedelics such as psilocybin and LSD. Receptor density recovers with abstinence, and tolerance resolves over days to weeks.
Physical dependence does not develop with serotonergic psychedelics, and there is no recognised withdrawal syndrome associated with the 2C-x class. Psychological dependence is low relative to many other psychoactive classes; the compulsive-use pattern characteristic of stimulants or opioids is not seen. The intense nature of the experience can nonetheless trigger lasting psychological distress, including hallucinogen persisting perception disorder (HPPD), particularly at higher doses or in unprepared settings.
Recovery
Discontinuation of a 2C-x compound does not require medical tapering and carries no withdrawal danger. Where recovery work is warranted it is psychological: supportive mental-health care addresses residual anxiety, mood disturbance, persistent perceptual changes, or distress tied to a difficult experience. A clinician familiar with psychedelic-associated phenomena, or an integration-oriented therapist, is the appropriate point of contact.
Recovery resources, crisis lines, and support pathways → View all
Members
references
- [1]
- [2]
- [3]^Luethi D, Trachsel D, Hoener MC, Liechti ME (2018) Monoamine receptor interaction profiles of 4-thio-substituted phenethylamines (2C-T drugs) — Neuropharmacology doi:10.1016/j.neuropharm.2017.07.012
- [4]^abcdPapaseit E, Olesti E, Perez-Mana C, Torrens M, Grifell M, Ventura M, Pozo OJ, de Sousa Fernandes Perna EB, Ramaekers JG, de la Torre R, Farre M (2020) Acute Effects of 2C-E in Humans: An Observational Study — Frontiers in Pharmacology doi:10.3389/fphar.2020.00233
- [5]^abcdWagmann L, Brandt SD, Stratford A, Maurer HH, Meyer MR (2019) Interactions of phenethylamine-derived psychoactive substances of the 2C-series with human monoamine oxidases — Drug Testing and Analysis doi:10.1002/dta.2494
- [6]^abcRickli A, Kopf S, Hoener MC, Liechti ME (2015) Pharmacological profile of novel psychoactive benzofurans — British Journal of Pharmacology doi:10.1111/bph.13128